Tech Acquisitions and Earnings Boost: Key Stocks on the Rise
Generado por agente de IAAinvest Market Brief
miércoles, 17 de julio de 2024, 6:30 pm ET1 min de lectura
GAN--
GFS--
PGR--
1. Globalfoundries (Unknown code: GFS)
Globalfoundries surged by 6.82%. Globalfoundries acquired GaN technology and IP from Tagore Technology to enhance efficiency and performance in automotive, IoT, and AI data centers. Cantor Fitzgerald reiterated its Neutral rating with a target price of $55.
2. The Progressive (NYSE: PGR)
The Progressive gained solidly by 5.42%. The Progressive reported Q1 2024 revenue of $17.243 billion, a 20.55% increase year-over-year. B of A Securities maintains a "Buy" rating with a latest target price of $293.00. JP Morgan maintains "Overweight" with a target price of $239.00. Keefe, Bruyette & Woods upgraded to "Outperform" with a target price of $245.00.
3. Bristol-Myers Squibbmpany (NYSE: BMY)
Bristol-Myers Squibbmpany gained solidly by 4.77%. Bristol-Myers Squibb has submitted a new indication application for its PD-1 inhibitor nivolumab in China. Barclays maintains its rating on the company as Equal-Weight with a new price target of $41.00.
4. U.S. Bancorp (NYSE: USB)
U.S. Bancorp gained solidly by 4.55%. U.S. Bancorp will announce its Q2 2024 financial results on July 17. Jefferies maintains a Hold rating, lowering its price target to $42. JP Morgan downgrades to Neutral with a $43.50 target. Evercore ISI rates In-Line, raising the target to $48.
5. Unitedhealth Group Incorporated (NYSE: UNH)
Unitedhealth Group Incorporated gained solidly by 4.43%. UnitedHealth Group reported second-quarter 2024 earnings, with revenue of $1986.51 billion, net income of $32 billion, and EPS of $3.05. Morgan Stanley, Jefferies, and Baird adjusted ratings and targets, with Morgan Stanley at $615, Jefferies at $647, and Baird at $640.
Globalfoundries surged by 6.82%. Globalfoundries acquired GaN technology and IP from Tagore Technology to enhance efficiency and performance in automotive, IoT, and AI data centers. Cantor Fitzgerald reiterated its Neutral rating with a target price of $55.
2. The Progressive (NYSE: PGR)
The Progressive gained solidly by 5.42%. The Progressive reported Q1 2024 revenue of $17.243 billion, a 20.55% increase year-over-year. B of A Securities maintains a "Buy" rating with a latest target price of $293.00. JP Morgan maintains "Overweight" with a target price of $239.00. Keefe, Bruyette & Woods upgraded to "Outperform" with a target price of $245.00.
3. Bristol-Myers Squibbmpany (NYSE: BMY)
Bristol-Myers Squibbmpany gained solidly by 4.77%. Bristol-Myers Squibb has submitted a new indication application for its PD-1 inhibitor nivolumab in China. Barclays maintains its rating on the company as Equal-Weight with a new price target of $41.00.
4. U.S. Bancorp (NYSE: USB)
U.S. Bancorp gained solidly by 4.55%. U.S. Bancorp will announce its Q2 2024 financial results on July 17. Jefferies maintains a Hold rating, lowering its price target to $42. JP Morgan downgrades to Neutral with a $43.50 target. Evercore ISI rates In-Line, raising the target to $48.
5. Unitedhealth Group Incorporated (NYSE: UNH)
Unitedhealth Group Incorporated gained solidly by 4.43%. UnitedHealth Group reported second-quarter 2024 earnings, with revenue of $1986.51 billion, net income of $32 billion, and EPS of $3.05. Morgan Stanley, Jefferies, and Baird adjusted ratings and targets, with Morgan Stanley at $615, Jefferies at $647, and Baird at $640.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios